AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Bitetti Teresa Marie sold $855K of TAK

Bitetti Teresa Marie (President, OBU) sold 50,012 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.86M total) on 2026-08-10.

Original reporting
SEC EDGAR · Bitetti Teresa Marie
Published Aug 13, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
low confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by an officer (OBU President), including price, share count, and holdings after the trade.

02

Market read

Traders may monitor for patterns in insider activity, but this single Form 4 does not introduce new company fundamentals.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing alone does not establish a bearish thesis on Takeda fundamentals.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralLow confidence
Context

Takeda’s Form 4 shows officer Teresa Marie Bitetti sold 50,012 shares at $17.10 on 2026-08-10, totaling $855,205.20.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless repeated or paired with other news.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no new operational, financial, or regulatory information about Takeda.

Market effects

Sector

Insider selling in pharma is generally not sector-moving without accompanying guidance, trial, or regulatory catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan can be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the issuer of the Form 4 insider transaction.

  • insider
    Teresa Marie Bitetti

    President, OBU, who sold shares via an open-market sale (Code S).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min